---
title: "Danaher: It is expected that the total tariff impact for the remainder of this year will reach $350 "
description: "Danaher: It is expected that the total tariff impact for the remainder of this year will reach $350 million"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/236979269.md"
published_at: "2025-04-22T12:48:20.000Z"
---

# Danaher: It is expected that the total tariff impact for the remainder of this year will reach $350 

> Danaher: It is expected that the total tariff impact for the remainder of this year will reach $350 million

Danaher: It is expected that the total tariff impact for the remainder of this year will reach $350 million

### Related Stocks

- [DHR.US - Danaher](https://longbridge.com/en/quote/DHR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Is Danaher (DHR) Attractive After Recent Share Price Weakness? | Danaher (DHR) shares have recently declined by 6.1% over the past week and 12.6% over the last month, currently priced a | [Link](https://longbridge.com/en/news/276201502.md) |
| Is It Too Late to Chase Masimo Stock on Major Danaher News? | Is It Too Late to Chase Masimo Stock on Major Danaher News? | [Link](https://longbridge.com/en/news/276240846.md) |
| Shares of Masimo, Danaher Moving on Acquisition Buzz | Danaher Corp is reportedly looking to acquire Masimo Corp for approximately $10 billion, causing Masimo's shares to surg | [Link](https://longbridge.com/en/news/276143275.md) |
| BREAKINGVIEWS-Danaher’s $10 bln M&A pivot demands faith | Danaher has announced a $9.9 billion acquisition of Masimo, a patient monitoring systems company, paying $180 per share, | [Link](https://longbridge.com/en/news/276155581.md) |
| M&A News: Danaher Nears $10B Deal for Masimo | Danaher (DHR) is nearing a $9.9 billion acquisition of Masimo (MASI), reflecting a significant premium over Masimo's mar | [Link](https://longbridge.com/en/news/276103321.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.